Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
about
The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment ResponseDendrimer advances for the central nervous system delivery of therapeuticsCurrent and potential imaging applications of ferumoxytol for magnetic resonance imaging.Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lyUSPIO-Enhanced MRI Neuroimaging: A Review.The in-vivo use of superparamagnetic iron oxide nanoparticles to detect inflammation elicits a cytokine response but does not aggravate experimental arthritis.Effects of ferumoxytol on quantitative PET measurements in simultaneous PET/MR whole-body imaging: a pilot study in a baboon model.A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging.Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young AdultsSafety and technique of ferumoxytol administration for MRI.Absence of Cytotoxicity towards Microglia of Iron Oxide (α-Fe2O3) Nanorhombohedra.Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation.Emerging applications for ferumoxytol as a contrast agent in MRI.Intrathecal magnetic drug targeting for localized delivery of therapeutics in the CNS.What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.Biodistribution of polyacrylic acid-coated iron oxide nanoparticles is associated with proinflammatory activation and liver toxicity.Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific.Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol.Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.Comparison of ferumoxytol-based cerebral blood volume estimates using quantitative R1 and R2* relaxometry.Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/SPECT imaging and flow cytometry.Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of α1 -adrenergic receptor antibodies.USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up.Dendrimers as Powerful Building Blocks in Central Nervous System Disease: Headed for Successful Nanomedicine
P2860
Q26773129-AC61F8CB-0645-453F-A5A3-7D0BDDAD5752Q26828423-871039F3-F69F-4DFA-B4ED-6E3D522898E6Q30234702-6E908649-21CB-4EB9-889D-17595E9C0C93Q30859319-10045125-2482-4D46-A595-0CE69F5B4A30Q30991629-AB32F3FB-29E8-48FF-9928-BEA5BE0C2345Q31051172-0DB29319-5806-473D-89D5-F89F95F881BFQ35587047-3EF94B05-77B6-4A67-8860-31C4D1E68551Q35981341-377DAD4E-A705-4D1E-A42A-715262602215Q36301599-F00097B8-9989-4F41-903B-E7DB2E96EF40Q36664896-41C39364-B9C4-4E16-8081-D98580F870F8Q36862859-56EB1AA1-1000-415F-AFDB-EC09FCC7E156Q36962295-1D775519-DD39-4F7D-BDEA-3C5B0B6C5823Q37724138-0C375E6A-AE0A-4880-AE78-B81F21A1D7D9Q38224182-ECFDB855-F303-4E60-87F9-FC0B8927CF0DQ38740343-060FBCD1-F221-4EB3-A50E-EEF4BC021064Q38790910-978E37E1-7A95-4B5C-A2E3-80CF0034EF94Q39832600-A81F188F-F17F-4C6E-9C3F-400545D8FF4AQ41763460-C4543B5D-8EA6-4BEF-9BC2-F9509D54F25BQ42516186-68AD9576-F0CC-4B47-8CBA-B47C0E475AC5Q46343256-E2531FC6-3B1A-4403-801A-EF38C496E00DQ47387857-6D8585EE-D6D9-49E9-AC25-CBAF7BF73D9AQ48166193-436F18A7-394B-4F0A-9BB4-29D618452CDDQ48638550-6FFF9CE0-EED1-4384-8FC7-F4DBED5E6403Q50076037-8CE126E6-1C72-43C6-9F5D-524CBCE72DFEQ57556323-93FAC5A7-42D6-4F34-92F6-8A6B2CB6EF1A
P2860
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
@en
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.
@nl
type
label
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
@en
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.
@nl
prefLabel
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
@en
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.
@nl
P2093
P2860
P1433
P1476
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
@en
P2093
Brian T Farrell
Bronwyn E Hamilton
Cynthia A Lacy
Endre Rimely
Eugene P Frenkel
Morad Nasseri
Nancy D Doolittle
Paula M Jacobs
Seymur Gahramanov
P2860
P304
P356
10.1212/WNL.0B013E31829BFD8F
P407
P577
2013-06-14T00:00:00Z